Investor Presentaiton

54 GBM (Newly-diagnosed) Phase 1/2 Study Trial Treatment (NCT03491683) . ● INO-5401 (3 mg of each WT1, PSMA and hTERT plasmids) combined with 1 mg INO-9012, (total 10 mg of DNA) IM injection followed by EP given every 3 weeks for 4 doses, then every 9 weeks; and Cemiplimab (LIBTAYOⓇ) (350 mg/dose IV every 3 weeks) Chemoradiation Treatment . • Radiotherapy (RT), given in a hypofractionated schedule (40 Gy over 3 weeks) for all patients post surgery Temozolomide (TMZ) concurrent with RT for all patients, and then following RT for 6 cycles in methylated patients only INOVIO POWERING DNA MEDICINES

View entire presentation